Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3receptor antagonist: a pilot study

• Published in: Alimentary pharmacology & therapeutics Vol. 28; no. 3; pp. 344 - 352
• Main Authors: JARCHO, JM, Chang, L, Berman, S M, SUYENOBU, B, Naliboff, B D, Lieberman, Md, Ameen, V Z, Mandelkern, Ma, Mayer, E A
• Format: Journal Article
• Language: English
• Published: 01.08.2008
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2008.03721.x

BackgroundSymptom improvement in irritable bowel syndrome (IBS) treatment trials varies widely, with only 50-70% of patients qualifying as responders. Factors predicting treatment responsiveness are not known, although we have demonstrated that symptom improvement with the 5-HT3R antagonist alosetron is correlated with reduced amygdala activity. AimTo determine whether neural activity during rectal discomfort or psychological distress predicts symptom improvement following treatment with alosetron. MethodsBasal psychological distress and neural activity (15O PET) during uncomfortable rectal stimulation were measured in 17 nonconstipated IBS patients who then received 3weeks of alosetron treatment. ResultsGreater symptom improvement was predicted by less activity in bilateral orbitofrontal cortex (OFC) and medial temporal gyrus during pre-treatment scans. Lower levels of interpersonal sensitivity predicted greater symptom improvement and were positively related to activity in left OFC. Connectivity analysis revealed a positive relationship between activity in the left OFC and right amygdala. ConclusionsIrritable bowel disease symptom improvement with 5-HT3R antagonist alosetron is related to pre-treatment reactivity of the left OFC, which may be partially captured by subjective measures of interpersonal sensitivity. The left OFC may fail to modulate amygdala response to visceral stimulation, thereby diminishing effectiveness of treatment. Psychological factors and their neurobiological correlates are plausible predictors of IBS treatment outcome.